Development and validation of a novel risk stratification signature derived from migrasome and tumor microenvironment-related genes for molecular subtyping and improving clinical outcomes in head and neck squamous cell carcinoma
Novel prognostic signature improves overall survival prediction in head and neck squamous cell carcinoma, highlighting tumor microenvironment effects.
Key Points
The novel migrasome and tumor microenvironment-related gene signature predicts overall survival in HNSCC patients, identifying distinct risk subgroups.
High-risk HNSCC patients showed significantly poorer overall survival rates compared to those in the lower risk category, as assessed by ROC and Kaplan-Meier analyses.
The risk stratification serves as an independent prognostic factor, with lower scores correlating to better responses to immunotherapy, especially CTLA4 inhibitors.
Analyzing mtmRGs enhances the understanding of immunotherapy sensitivity and informs tailored treatment plans for HNSCC patients.